查詢結果分析
相關文獻
- Complications of Membrane-Filtration Plasma Exchange
- B型流感併發重症及格林-巴利症候群:案例報告及文獻回顧
- 混凝-薄膜過濾系統對膠體顆粒去除效率之探討
- HELLP Syndrome with Antepartum Pulmonary Edema--A Case Report
- Ephedrine-Induced Complete Atrioventricular Block with Ventricular Asystole during Rapid Concomitant Phenytoin Infusion: A Case Report
- Epiglottic Hematoma Secondary to Endotracheal Intubation
- 臺灣地區慢性脊髓損傷病患排尿處置之調查報告
- 小兒使用TPN引起的併發症
- 淺談糖尿病及其併發症
- 難忘的病人--民俗療法之併發症
頁籤選單縮合
題 名 | Complications of Membrane-Filtration Plasma Exchange=薄膜過濾血漿置換治療之併發症 |
---|---|
作 者 | 吳明儒; 徐國雄; 鄭志雄; 連榮達; | 書刊名 | 中華醫學雜誌 |
卷 期 | 60:3 1997.09[民86.09] |
頁 次 | 頁147-154 |
分類號 | 415.74 |
關鍵詞 | 併發症; 薄膜過濾; 血漿減除術; 血漿置換術; Complication; Membrane-filtration; Plasmapheresis; Plasma exchange; |
語 文 | 英文(English) |
中文摘要 | 背景:血漿置換術在過去二、三十年間,已經被廣泛地使用於治療多種疾病。雖然血漿置換術通常被認為是一種還算安全的治療,卻仍然有一些不好的副作用可能發生。為突顯對此種治療品質之要求,我們回溯性探討十三年來接受血漿置換治療之病例。 方法:自1983年4月至1996年3月,在本院接受薄膜過濾方法的血漿置換治療中,有完整病歷記錄的157人、694次治療均列入統計。我們使用Plasma floop-05(L)薄膜過濾器,而且以一個血漿容積的新鮮冷凍血漿作為補充液。我們回溯所有血漿置換治療的治療記錄以及臨床病歷記錄,評估其併發症與成效。 結果:總計157人、694次治療中,有84位男性及73位女性,年鹼介於1至75歲(中位數:35歲),平均治療次數的中位數是4次(介於1次至34次)。其中最常治療的幾種疾病分別是:嚴重黃疸(41.1%), 紅斑性狼瘡(23.6%),以及重症肌無力(15.3%)。所有血漿置換治療的有效率尚可接受(40.8%),特別是神經性疾病的效果最好(91.4%)。然而併發症的發生率佔總人數的 36%,總次數的 59.2%。 最常發生的不良反應分別是:感覺異常(12.7%),畏寒(10.2%),胸痛(5.9%),噁心(2.9%)及呼吸困難(2.0%)。此外,其他併發症包括導管感染(0.3%)導管滲血(1.2%),頭暈(1.3%),頭痛(0.4%),肌肉痙攣(1.3%), 嘔吐(0.4%),腹痛(0.9%),發燒(0.3%), 低血壓(1.3%),出血(0.4%),昏迷(0.7%)呼吸停止(0.4%)。然而併發症中輕微症狀者佔23%,中度症狀者佔11.4%,重度症狀者佔1.6%。但是沒有任何一位病患在血漿置換治療後24小時內死亡。 結論:雖然薄膜過濾方式的血漿置換治療是一種有療效、而且還算安全的治療,仍有一些致命性的併發症會發生。 |
英文摘要 | Background: Plasma exchange (PE) has been extensively used to treat a variety of disease states in the past three decades. Although PE is commonly thought to be a relatively safe procedure, a number of unpleasant side effects may occur. To highlight the need for continuing quality assurance in providing PE service, a retrospective review of PE records over a 13-year period was undertaken. Methods: From April 1983 to March 1996, 694 therapeutic PE procedures, membrane-filtration type, were performed on a total of 157 patients in this hospital. Plasmaflo op-05(L) (Asahi Japan) was used as the plasma separator and fresh frozen plasma of one plasma volume as replacement fluid. The PE sheets for all procedures were reviewed as were medical charts in order to evaluate clinical efficacy. Results: Totally 694 PEs in 157 patients, 84 male and 73 feamales, ranging in age from 1 to 75 years (median, 35 years), were treated. Patients received a median of 4 treatments (range, 1 to 34). The most frequent indications were severe jaundice (41.4%), systemic lupus erythematosus (23.6%), and myasthenia gravis (15.3%). The overall effective rate was 40.8%, and was best in neurological diseases (91.4% effective). Complications of PE were noted during 36% of the procedures involving 59.2% of the patients treated. The most common adverse reactions were paresthesia (12.7%), chills (10.2%), urticaria (8.5%), chest pain (5.9%), nausea (2.9%) and dyspnea (2.0%). Less common complications included: catheter infection (0.3%), catheter oozing (1.2%), dizziness (1.3%), headache (0.4%), muscle cramps (1.3%), vomiting (0.4%), abdominal pain (0.9%), fever (0.3%), hypotension (1.3%), bleeding (0.4%), consciousness change (0.7%) and respiratory arrest (0.4%). These complications were classified as "mild" (23%), "moderate" (11.4%) and "severe" (1.6%). No deaths occurred within 24 hours after PE. Conclusions: Although the use of membrane-filtration PE represents a valuable and relatively safe therapy, some life-threatening reactions do occur. |
本系統中英文摘要資訊取自各篇刊載內容。